off-the-shelf– tag –
-
Fate Therapeutics to Announce iPSC-Derived Immunocellular Therapy Strategy at 2026 Cantor Conference
GlobeNewswire USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. The company holds a leading position in creating multi-gene-edited iPSC lines and manufac... -
Fate Therapeutics to Present on iPSC-Derived CAR T Cell Candidate FT819 for Autoimmune Diseases at 2026 Cantor Global Healthcare Conference
Stock Titan USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 9th, where it will discuss its off-the-shelf iPSC-derived CAR T cell candidate FT819 f... -
Fate Therapeutics Initiates Phase 1/2 Trial for Novel Cell Therapy FT839 in Autoimmune Diseases, Expanding Pipeline
TipRanks.com USA Overview Fate Therapeutics has launched a Phase 1/2 dose-escalation and expansion trial for its novel cell therapy candidate, FT839, in patients with autoimmune diseases. This intravenously administered therapy is design... -
Fate Therapeutics Initiates Phase 2 RECLAIM-LN Trial for Lupus Nephritis with Off-the-Shelf iPSC-Derived CD19 CAR-T Cell Therapy FT819
Seeking Alpha USA Overview Fate Therapeutics has commenced its Phase 2 RECLAIM-LN trial for lupus nephritis, administering the first patient with its iPSC-derived CD19 CAR-T cell therapy, FT819, in an outpatient setting. This marks a sig... -
CRISPR Therapeutics Diversifies Pipeline into In Vivo Gene Editing and Off-the-Shelf CAR-T Cell Therapies, Leveraging Casgevy Commercialization Experience
Venture Atlas USA Overview CRISPR Therapeutics is strategically diversifying its pipeline, leveraging its commercialization experience with Casgevy, into in vivo gene editing programs (CTX310, CTX320, CTX340, CTX460) and allogeneic off-t... -
XellSmart’s iPSC Parkinson’s Therapy XS411 Granted FDA Fast Track Designation, Accelerating Commercialization
Longevity.Technology UK Overview XellSmart's XS411, an allogeneic iPSC-derived cell therapy for Parkinson's disease, has received FDA Fast Track designation. This designation aims to expedite the development and review of therapies for s... -
Commercial-Scale iPSC Cell Therapy: Advancements in Off-the-Shelf Treatments, Immunogenicity, and Cost Reduction are Key
The Medicine Maker UK Overview This article examines the challenges and technological advances in scaling induced pluripotent stem cell (iPSC) platforms for commercial cell therapies. It highlights the shift towards allogeneic, off-the-s... -
Xellsmart Secures FDA Fast Track Designation for Parkinson’s iPSC-Derived Cell Therapy, Accelerating CNS Pipeline
Longevity.Technology UK Overview Xellsmart announced its allogeneic, off-the-shelf iPSC-derived cell therapy for Parkinson's disease has received FDA Fast Track designation, expected to accelerate its development program. Specializing in... -
CellFiber and Tidewave Bio Partner to Advance Next-Generation Solid Tumor Immunotherapy Manufacturing Scale-Up via 3D Cell Culture Platform
(Biotech News) Japan Overview CellFiber and Tidewave Bio announced a strategic collaboration to evaluate CellFiber's 3D cell culture platform for the scalable manufacturing of Tidewave's next-generation cell immunotherapy. This proof-of-... -
Virica Biotech Announces CAR-T Lentivirus Manufacturing Innovations and AAV Production Optimization with FUJIFILM
Virica Biotech Canada Overview Virica Biotech has announced innovative advancements in lentiviral vector manufacturing for CAR-T therapies, highlighted by a May 19, 2026, poster presentation featuring high productivity and smarter purifi...
